PLX Protalix BioTherapeutics Inc. (DE)

-0.02  -7%
Previous Close 0.25
Open 0.24
Price To Book -0.51
Market Cap 34,276,311
Shares 148,382,299
Volume 239,043
Short Ratio 10.58
Av. Daily Volume 422,520

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 trial 11 patients away from full enrolment.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
Ulcerative Colitis
Phase 3 BRIDGE completion of enrolment announced December 17, 2018 with additional data due 2019. BLA filing due 1Q 2020.
Pegunigalsidase alfa (PRX-102) BRIDGE
Fabry disease
Phase 3 completion of enrolment announced June 17, 2019.
Pegunigalsidase alfa (PRX-102) - BRIGHT
Fabry disease

Latest News

  1. Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
  2. Edited Transcript of PLX earnings conference call or presentation 8-Aug-19 12:30pm GMT
  3. Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates
  4. Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update
  5. Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  6. Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019
  7. Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
  8. Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?
  9. Protalix (PLX) Completes Enrollment in Fabry Disease Study
  10. Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
  11. Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
  12. Why Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.'s (WSE:PLX) High P/E Ratio Isn't Necessarily A Bad Thing
  13. Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
  14. Edited Transcript of PLX earnings conference call or presentation 6-May-19 12:30pm GMT
  15. Przetwórstwo Tworzyw Sztucznych Plast-Box S.A. (WSE:PLX) Delivered A Weaker ROE Than Its Industry
  16. Protalix: 1Q Earnings Snapshot
  17. Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update
  18. Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
  19. Is Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX) CEO Being Overpaid?